These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 19402802)

  • 21. Pharmaceutical patent settlements: the antitrust risks.
    Balto DA
    Food Drug Law J; 2000; 55(3):321-41. PubMed ID: 11824464
    [No Abstract]   [Full Text] [Related]  

  • 22. Biosimilar medicines--new challenges for a new class of medicine.
    Fox A
    J Biopharm Stat; 2010 Jan; 20(1):3-9. PubMed ID: 20077245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biosimilars in the United States: Emerging Issues in Litigation.
    Wong AY; Rumore MM; Chan AW
    BioDrugs; 2017 Jun; 31(3):189-205. PubMed ID: 28424972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biologic Drugs, Biosimilars, and Barriers to Entry.
    Shepherd JM
    Health Matrix Clevel; 2015; 25():139-61. PubMed ID: 29485844
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biosimilars: the need, the challenge, the future: the FDA perspective.
    Epstein MS; Ehrenpreis ED; Kulkarni PM;
    Am J Gastroenterol; 2014 Dec; 109(12):1856-9. PubMed ID: 24957160
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Implementation of the biosimilar pathway: economic and policy issues.
    Grabowski H; Long G; Mortimer R
    Seton Hall Law Rev; 2011; 41(2):511-57. PubMed ID: 21739758
    [No Abstract]   [Full Text] [Related]  

  • 27. Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future.
    Grabowski HG; Guha R; Salgado M
    Health Aff (Millwood); 2014 Jun; 33(6):1048-57. PubMed ID: 24889955
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generic drugs: the stalling game.
    Consum Rep; 2001 Jul; 66(7):36-40. PubMed ID: 11725791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulatory Approaches and Considerations in Establishing Bioequivalence of Inhaled Compounds.
    Mayers I; Bhutani M
    J Aerosol Med Pulm Drug Deliv; 2018 Feb; 31(1):18-24. PubMed ID: 28708443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Settlements between brand and generic pharmaceutical companies: a reasonable antitrust analysis of reverse payments.
    Yvon AM
    Fordham Law Rev; 2006 Dec; 75(3):1883-912. PubMed ID: 17312596
    [No Abstract]   [Full Text] [Related]  

  • 31. Pharmaceuticals: generic/ therapeutic drug substitution: year end report-2002.
    Floridi T; Kammer C
    Issue Brief Health Policy Track Serv; 2002 Dec; ():1-12. PubMed ID: 12856672
    [No Abstract]   [Full Text] [Related]  

  • 32. Biosimilar drugs : concerns and opportunities.
    Genazzani AA; Biggio G; Caputi AP; Del Tacca M; Drago F; Fantozzi R; Canonico PL
    BioDrugs; 2007; 21(6):351-6. PubMed ID: 18020619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Developing the nation's biosimilars program.
    Kozlowski S; Woodcock J; Midthun K; Sherman RB
    N Engl J Med; 2011 Aug; 365(5):385-8. PubMed ID: 21812668
    [No Abstract]   [Full Text] [Related]  

  • 34. Frontiers in nonclinical drug development: biosimilars.
    Ryan AM
    Vet Pathol; 2015 Mar; 52(2):419-26. PubMed ID: 25161206
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Substituting generic drugs: state roles.
    Cauchi R
    NCSL Legisbrief; 2009; 17(25):1-2. PubMed ID: 19526654
    [No Abstract]   [Full Text] [Related]  

  • 36. Democrats prioritize pricing, generics and drug safety.
    Fox JL
    Nat Biotechnol; 2007 Feb; 25(2):150-1. PubMed ID: 17287735
    [No Abstract]   [Full Text] [Related]  

  • 37. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.
    Ahmed I; Kaspar B; Sharma U
    Clin Ther; 2012 Feb; 34(2):400-19. PubMed ID: 22244050
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The end of the beginning?
    Nat Biotechnol; 2006 Apr; 24(4):367. PubMed ID: 16601702
    [No Abstract]   [Full Text] [Related]  

  • 39. Biosimilars.
    Malozowski S
    Arq Bras Endocrinol Metabol; 2011 Nov; 55(8):669. PubMed ID: 22218453
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biosimilars: Rationale and current regulatory landscape.
    Olech E
    Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S1-10. PubMed ID: 26947438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.